Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial

详细信息    查看全文

• 作者：Daigo Yamamoto ; Nobuaki Sato ; Yoshiaki Rai…
• 关键词：Capecitabine ; Docetaxel ; HER2 ; negative ; Anthracycline ; pretreated ; Metastatic breast cancer
• 刊名：Breast Cancer Research and Treatment
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：161
• 期：3
• 页码：473-482
• 全文大小：
• 刊物类别：Medicine
• 刊物主题：Oncology;
• 出版者：Springer US
• ISSN：1573-7217
• 卷排序：161

文摘

PurposeThe randomized phase III JO21095 trial compared the efficacy and safety of low-dose capecitabine plus docetaxel combination therapy (XT) versus single-agent administration of docetaxel in anthracycline-pretreated HER2-negative metastatic breast cancer.